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Abstract 
Background: To describe patterns of antibiotic outpatient use in three European countries, 
including two new pediatric-specific quality indicators (QIs). 
Methods: A cohort study was conducted, 2001-2010, using electronic primary care records of 
2,196,312 children up to 14 (Pedianet, Italy) or 18 years (THIN, UK; IPCI, the Netherlands) 
contributing 12,079,620 person-years. Prevalence rates of antibiotic prescribing per year were 
calculated and antibiotics accounting (drug utilization) for 90% of all antibiotic prescriptions 
were identified (DU90% method). The ratio between users of broad to narrow-spectrum 
penicillins, cephalosporins and macrolides (B/N ratio) and two pediatric-specific quality 
indicators (QIs): the proportion of amoxicillin users (amoxicillin index, AI) and the ratio 
between users of amoxicillin to broad-spectrum penicillins, cephalosporins and macrolides (A/B 
ratio) were determined. 
Results: The overall annual prevalence of antibiotic prescriptions was 18.0% in the Netherlands, 
36.2% in the UK and 52.0% in Italy. Use was maximal in the first years of life. The number of 
antibiotics accounting for the DU90% was comparable. The B/N ratio varied widely from 0.3 to 
74.7. The AI was highest in the Netherlands and the UK (50-60%), lowest in Italy (30%) and 
worsened over time in the UK and Italy. The A/B ratio in 2010 was 0.3 in Italy, 1.7 in the 
Netherlands and 5.4 in the UK.  
Conclusions: The patterns of antibiotic prescribing varied highly with age and country. The 
pediatric-specific QIs combined with the total prevalence rate of use provide a clear picture of 
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the trends of community childhood antibiotic prescribing, allowing monitoring of the impact of 
policy interventions. 
Keywords: outpatient, pediatrics, antibiotic, quality, pharmacoepidemiology 
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Introduction 
Despite clear evidence that poorly targeted antibiotic use contributes to the major health problem 
of antimicrobial resistance, outpatient antibiotic prescribing in Europe remains high with a strong 
north-south gradient. 
1-3
. Children are high consumers of antibiotics especially in the first years 
of life 
4, 5
. Indeed, high rates of antibiotic prescribing in primary care, often for acute respiratory 
tract infections (RTIs) 
6
, warrant close monitoring of childhood prescribing patterns. Yet, there 
have been few initiatives so far to assess quality of outpatient antibiotic prescribing in children 
7
. 
Quality indicators (QIs) have already been developed within the context of the European 
Surveillance of Antimicrobial Consumption (ESAC) project 
8
 based on outpatient use data. 
However, these QIs are not directly applicable to pediatric antibiotic use because of the absence 
of age-specific pediatric defined daily dosages (DDDs) and age-related differences in the 
prevalence of infections and patterns of drug use between adults and children.  
The Antibiotic Resistance and Prescribing in European children (ARPEC) project, aimed to 
improve antimicrobial prescribing in hospitals and in the community, by obtaining up-to-date, 
relevant data on variation in clinical management and antimicrobial resistance rates. Within this 
sub-project of ARPEC, we sought to describe patterns of antibiotic use in pediatric primary care 
in three European countries using, amongst others, two newly proposed pediatric-specific quality 
indicators.  
 
Patients and Methods 
Study design and Data sources   
This study is a retrospective cohort study. Data were collected from three population based 
primary care databases in the Netherlands (NL), the United Kingdom (UK) and Italy (IT). In NL 
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and UK, general practitioners (GPs) are responsible for the primary care of children. The 
Integrated Primary Care Information database (IPCI) from NL comprises electronic medical 
records from more than 400 Dutch GPs since 1996 
9, 10
. The Health Improvement Network 
(THIN) is a database of primary care medical records from UK, prospectively collecting data 
since September 2002 and containing retrospective data since the late 1980’s 11. In Italy, family 
pediatricians (FPs) are the gatekeepers of primary care for children less than 14 years of age. The 
Pedianet database contains exclusively pediatric electronic medical records from 150 FPs in IT 
since 2000 
12
. These databases contain the complete automated patient files, with detailed 
information on population, diagnoses and drug prescriptions. Their use has been proven valid for 
pharmacoepidemiologic research and data are representative of national pediatric populations 
with regard to gender and age distribution 
11, 13
. Details about their structure have been described 
elsewhere 
9, 10, 12, 14
.  
Data from the different databases were pooled using a distributed network approach, in which 
dataholders maintain control over their original data and only anonymized and aggregated data 
are shared. This was done through generation of data into a common format followed by local 
data aggregation using custom-built software, Jerboa
©
 
15
. The respective scientific and ethics 
committees of each database approved the conduct of the study. 
Study period  
As the start date for data collection differed between databases, the start of the study period was 
defined as the 1
st
 January 1995 for the UK, the 1
st
 January 1996 for the Netherlands and the 1
st
 
January 2001 for Italy. The study period ended on the 31
st
 December 2010. 
Children were followed from the start of entry into the study (start of study period, date of 
registration plus 6 months (except for newborns) until their 18
th
 (NL and UK) or 14
th
 (IT) 
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birthday, the end of the study period, leaving the practice, death, or latest data recorded, 
whichever came first. 
Patterns and quality of antibiotic use  
All antibiotics under the therapeutic subgroup J01 ‘Antibacterials for systemic use’ of the 
Anatomical Therapeutic Chemical (ATC) classification system 
16
 were included in the study. 
The proportion of children being prescribed antibiotics and the number of individual drugs 
accounting for 90% of drug use, called drug utilization 90% (DU90%), have been proposed as 
indicators of the quality of antibiotic prescribing 
17-19
. Annual prevalence rates were expressed as 
the number of users per 100 person years (PYs) notated as a percentage to be interpreted as the 
number of children per 100 who use an antibiotic drug or drug class in one year. For the 
numerator, the number of children that received at least one prescription for an antibiotic drug or 
drug class within a calendar year was assessed. Because of the dynamic nature of the population, 
we used person time rather than total number of individuals as denominator. To account for the 
large differences in antibiotic use within the pediatric population, ranging from neonates to 
adolescents, prevalence was stratified in one-year age categories (0-<1 years etc.) and in broader 
age-categories; 0-<1 years, 1-<5 years, 5-<12 years and 12-<18 years. Similarly, prevalence of 
use was calculated at ATC 3
th 
(pharmacological subgroup) and 5
th 
(active substance) levels. Also, 
the number and type of antibiotics that covered 90% of all antibiotic prescriptions (DU90%) 
were assessed and presented by country, calendar year and age category. 
Further, one of the ESAC QIs, the ratio between the number of users of broad-spectrum (J01CR, 
J01DC, J01DD and J01F [without erythromycin]) to those of narrow-spectrum penicillins, 
cephalosporins and macrolides (J01CE, J01DB and J01FA01), the B/N ratio, was determined. 
This ratio gives an estimate of the balance between prescribing of broad- versus narrow-
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spectrum antibiotics. So the smaller the B/N ratio, the most appropriate the prescribing
8
. Two 
new QIs more relevant for children were estimated based on amoxicillin use: 1) the proportion of 
amoxicillin users (J01CA04) among all antibiotic users (J01) - the amoxicillin index (AI), and 2) 
the ratio between the number of amoxicillin users (J01CA04) and the number of users of broad-
spectrum penicillins, cephalosporins and macrolides (J01CR, J01DC, J01DD and J01F [without 
erythromycin]) - the amoxicillin to broad-spectrum ratio (A/B ratio). This ratio gives an estimate 
of the use of a first-line and relatively narrower-spectrum penicillin antibiotic to that of broader-
spectrum penicillins, cephalosporins and macrolides in children. Thus, the greater the A/B ratio, 
the most appropriate the prescribing. All three ratios were stratified by country, age categories 
and calendar year.  
Statistical analysis 
Data were described in narrative and tabular forms. For each country, a Poisson regression model 
was applied to determine the influence of increasing calendar year on yearly antibiotic 
prevalence rates. Statistical analyses were performed using the SAS software version 9.3 
software (SAS Inc, Cary, North Carolina). 
 
Results 
In this population-based cohort study a total of 2,195,312 children were included: 239,293 from 
NL (10.9%), 1,725,798 from UK (78.6%), and 230,275 from IT (10.5%) who altogether 
contributed 12,079,620 PYs of follow up. 
Overall antibiotic use  
The overall annual prevalence of antibiotic prescriptions for NL, UK and IT was 18% (18 
users/100PYs), 36% and 52%, respectively. The time trends for the three countries are shown in 
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Figure 1. The prevalence of antibiotic prescription in the UK and IT slightly decreased with 
increasing calendar years (RR=0.995, p-value <0.001 and RR=0.997, p-value <0.001), whereas it 
remained stable in NL (RR=0.999, p-value =0.42).  
Penicillins with extended spectrum (J01CA) were the most frequently prescribed antibiotics 
particularly in the first years of life (Figure 2). Overall, the most commonly prescribed antibiotic 
was amoxicillin: 9.2 % in NL, 19.7% in the UK and 18% in IT. Amoxicillin prescriptions peaked 
at the age of one to two years with a maximum of 30.5% in NL, 46% in the UK and 31.3% in IT. 
Prescriptions for the class ‘combinations of penicillins, incl. beta-lactamase inhibitors’ (J01CR) 
were frequent in NL and IT, while in the UK beta-lactamase sensitive penicillins were very 
frequently prescribed (J01CE). 
In the macrolides class (J01FA), erythromycin was the main antibiotic prescribed in the UK, 
with a prevalence rate of 4.5%, peaking at one to two years of age (8.7%). In NL, clarithromycin 
(1.1%; maximal 3.3% at one to two years) and azithromycin (1.6%; maximal 3.4% at one to two 
years) were predominant. In IT, the prevalence rate of clarithromycin was 7.1% (maximal 11.1% 
at three to four years) and that of azithromycin was 7.6% (maximal 12.8% at three to four years).  
The prevalence of second and third generation cephalosporins (J01DC-DD) was high in IT, up to 
4.1% and 6.8% at three to four years of age (Figure 2), while in the UK and NL prevalence of 
cephalosporin use (J01D) was low (2.3%) and very rare (0.02%), respectively. In IT, third-
generation cephalosporins made up a large proportion of cephalosporin prescribing: cefixime 
(2.8% at three to four years), cefpodoxime (2% at three to four years) and ceftibuten (1.1% at 
one to two years).  
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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Ninety per cent of all antibiotic prescriptions (DU90%) in this population were covered by 9 
drugs in NL and by 8 drugs in both UK and IT. In NL and UK, the number of drugs accounting 
for the DU90% increased with age, while this number was stable in Italy (table 1 a-c). 
Quality Indicators 
The B/N ratio was highest in IT for all ages and all calendar years. Across all three countries, the 
B/N ratio was highest in the youngest children: 5.7 in infants aged below one year in NL and 0.4 
and 100.1 in children aged one to four years in the UK and IT, respectively. When comparing 
calendar years 2001, 2006 and 2010, the B/N ratio increased slightly in the UK and in NL 
whereas it multiplied by 10 between 2001 and 2010 in IT (table 2). 
The AI was highest in infants aged less than 1 year: 80% in NL and the UK and approximately 
50% in IT (figure 3.1). Overall, this percentage remained stable between 2001 and 2010 in NL 
whereas it slightly decreased in the UK and in IT (figure 3.2).  
The UK had the highest A/B ratio in all age categories (Table 3). In NL, the A/B ratio was also 
high however, the ratio decreased with increasing age; in adolescents between 14 and 18 years of 
age, users of broad-spectrum antibiotics were nearly twice those of amoxicillin. In IT, broad-
spectrum antibiotics were more commonly prescribed than amoxicillin in all age categories, 
though again the difference increased with increasing age. Over the years, the overall number of 
users of amoxicillin compared to that of broad-spectrum antibiotics increased in NL whereas it 
decreased in the UK and in IT.  
 
Discussion  
In this cohort study we describe patterns of primary care prescribing of antibiotic agents in 
children in three European countries. More than 2 million children aged 0-<18 years were 
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
11 
 
included, contributing over 12 million PYs of follow up through a period of 10 to 16 years. 
Based on this large cohort, we were able to demonstrate the application of two new QIs of 
pediatric community-based antibiotic prescribing, the AI and the A/B ratio.  
Expectedly, we found that the antibiotic prescribing prevalence rates were lowest in NL (18% 
per year), 36% per year in the UK and highest in IT (52% per year) 
4, 5, 20
. Antibiotic prescribing 
tended to slightly decrease over time in all countries, though this decrease was not statistically 
significant in NL. Although there was considerable variability in the type of antibiotics that were 
most commonly prescribed, amoxicillin was the most commonly prescribed antibiotic in all three 
countries. However, the number of antibiotics making up the DU90% was similar across the 
three countries, demonstrating the limited repertoire of antibiotics making up the bulk of 
community-based antibiotic prescribing for children. These findings are in line with recent 
European data also placing IT and NL at the two extremes of antibiotic use and Germany, UK 
and Denmark between those extremes, at decreasing prevalence rates 
21, 22
. 
Broad-spectrum antibiotic prescribing increased in all countries in the studied period and was 
highest in IT. The B/N ratio was highest in the youngest children. The overall ratios for children 
were somewhat lower than the ESAC findings for adults in 2004 for the UK (0.3 vs. 0.56) and 
NL (3.2 vs. 5.12), and higher in Italy (74.7 vs. 50.9) 
8
. For pediatric patients, this ratio is highly 
variable and hard to interpret especially as certain drugs, such as penicillin V 
(phenoxymethylpenicillin), are not available in specific countries. 
We developed and assessed two new simple QIs to evaluate the quality of community-based 
antibiotic prescribing, the AI and the A/B ratio, which revealed important differences in 
antibiotics prescribed, both between age groups and countries. The AI was highest in the UK and 
NL (50%) and lowest in IT (30%), which is compatible with the much higher annual exposure of 
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Italian children to macrolides, to penicillins with beta-lactamase inhibitors and to 3
rd
/4
th
 
generation cephalosporins. The A/B ratio provided further detail. This ratio was highest for the 
UK (A/B ratio of 6, that is 6 amoxicillin users observed for one broad-spectrum antibiotic user in 
a given calendar year) followed by NL (A/B ratio of 2). Together with the AI, this can be 
interpreted as greater prescribing preference for narrower-spectrum antibiotics, such as beta-
lactamase susceptible penicillins, as alternatives to amoxicillin in the UK compared to NL. Thus, 
although overall prescribing in NL is lower than in the UK, children receiving antibiotics are 
more likely to be prescribed broader-spectrum agents than in the UK. In IT, the A/B ratio is 
reversed (<1), indicating that prescriptions of broad-spectrum agents are altogether more 
common than amoxicillin prescriptions.  
The selection of amoxicillin as the reference standard to evaluate the quality of antibiotic 
prescribing may seem somewhat arbitrary. However, upper and lower respiratory tract infections 
remain by far the most common indications for childhood antibiotic prescribing in community 
practice 
5, 23
. Many guidelines recommend amoxicillin as the first-line choice for suspected 
bacterial respiratory tract infections, including pneumonia and otitis media.
24-27
 Several patterns 
in our data support the role of amoxicillin in assessing antibiotic prescribing quality in the 
childhood population. In all three countries, seasonal variation with peak prescribing in winter, in 
line with the seasonal trend of the incidence of acute respiratory infections, was observed (data 
not shown) 
28
. The high AI in NL and the UK as well as the substantial contribution of 
macrolides and penicillins combined with beta-lactamase inhibitors in IT support the 
interpretation that a large proportion of childhood community-based antibiotic prescribing targets 
acute respiratory infections. The AI was highest in the youngest children, who are also most 
frequently treated with antibiotics for respiratory infections 
29, 30
. Equally a drop in the A/B ratio 
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from infancy to preschool age may be partially explained by the increasing use of macrolides 
with increasing age due to the unresolved questions about the need to cover for atypical 
pathogens in older children 
31
 . 
As many prescriptions are likely to be issued to children with viral respiratory infections, efforts 
are needed to reduce prescribing in this setting 
32
. Amoxicillin consumption could reflect the part 
of antibiotic use in children that has the greatest potential for reduction 
5
. In the 15 years covered 
by this study considerable effort has been put in reducing inappropriate prescriptions of 
antibiotics in Europe 
7, 33, 34
. Despite these efforts, the overall change in prevalence rates 
observed in this study over time was very small. Yet, major interventions can effectively reduce 
inappropriate antibiotic prescribing 
35
. In France, national campaigns focusing on inappropriate 
antibiotic prescribing for respiratory tract infections of viral origin in children aged 0 to 6 years 
reported a 35.8% reduction in antibiotic prescriptions
36
.  
However, beyond aiming to achieve an overall reduction in antibiotic prescribing, it may also be 
necessary to improve the quality of antibiotic selection. In the UK, narrow-spectrum penicillins 
were the second most commonly prescribed antibiotic class after amoxicillin whereas in NL 
amoxicillin with enzyme inhibitor and macrolides were preferred. In IT, third-generation oral 
cephalosporins and macrolides were very commonly used together with amoxicillin with or 
without enzyme inhibitor, a pattern that has already been described in previous drug utilization 
studies 
37
. Likewise, use of broad-spectrum antibiotics, oral cephalosporins and macrolides, in 
Germany has been noted as comparable to that of IT whereas antibiotic prescriptions in Denmark 
concern almost exclusively narrow-spectrum agents
21, 22
. Differences in prescribed antibiotics 
among the countries can partly be explained by availability of antibiotics and differences in 
guidelines. For example, penicillin V is not available in Italy whereas it is widely used in the 
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UK. For the treatment of acute pharyngitis, amoxicillin is the first choice in IT with second 
generation cephalosporins considered second line, while in other countries use of narrow-
spectrum penicillins is more strongly recommended
38-40
. To improve community-based antibiotic 
prescribing, antibiotic stewardship should target both volume of antibiotic use and agent 
selection. While such interventions have been successfully implemented in the US, on-going 
activities are required to sustain any improvements
41
.  
In the absence of pediatric DDDs, we reported total and class specific consumption as prevalence 
rates, which may also be more explicit for primary care physicians. We also derived two simple 
new QIs which provide useful information and trends over time, but need to be age-specific since 
both antibiotic prescribing and the prevalence of infectious diseases are age-dependent. A key 
limitation of the current study is that we could not stratify our results by clinical indications as 
the latter were not collected. In future studies, stratification by indication may give more insight 
in the quantitative and qualitative differences of antibiotic prescribing between countries. It can 
also provide valuable epidemiological information by drawing inferences on the proportion of 
children treated for a specific indication. This information is crucial to assess whether antibiotic 
prescribing policies can be further optimized.  
In conclusion, assessment of antibiotic consumption in these three countries identified distinct 
patterns of use. In the UK, prevalence of antibiotic prescribing remains moderately high with 
only a slight reduction in global and amoxicillin use over time; however prescribing of broad-
spectrum antibiotics is low. Conversely in NL consumption of antibiotics is low and remains 
stable, but broad-spectrum antibiotic prescribing is progressively increasing compared to narrow-
spectrum classes. Finally, antibiotic prescription patterns in IT are dominated by broad-spectrum 
agents. These patterns were most easily visualised and evaluated using two new simple quality 
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indicators of childhood community-based antibiotic prescribing, the Amoxicillin Index and the 
Amoxicillin to Broad-spectrum Antibiotic Ratio. Crucially, total antibiotic prevalence of use and 
the two new pediatric-specific quality indicators may inform the evaluation of existing national 
interventions to reduce and improve antibiotic prescribing and, most importantly, may help to 
adequately design future interventions in this area.  
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Table 3.  
Ratio of users of amoxicillin to users of broad-spectrum penicillins, cephalosporins and 
macrolides per database, age category and calendar year 
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Table 1a. Antibiotics that cover 90% of all antibiotic prescriptions (DU90%) by age categories in 
the Netherlands (1996-2010) 
Age 0-<1 years Age 1-<5 years Age 5-<12 
years 
Age 12-<18 
years 
Overall 
Amoxicillin 
(73.2%) 
Amoxicillin 
(57.8%) 
Amoxicillin 
(43.8%) 
Amoxicillin 
(17.2%) 
Amoxicillin 
(45.1%) 
Amoxicillin and 
enzyme 
inhibitor 
(10.4%) 
Amoxicillin and 
enzyme 
inhibitor 
(14.0%) 
Amoxicillin 
and enzyme 
inhibitor  
(16.5%) 
Doxycycline  
(12.3%) 
Amoxicillin and 
enzyme inhibitor  
(13.5%) 
Clarithromycin 
(5.7%) 
Azithromycin 
(7.6%) 
Azithromycin 
(8.0%) 
Nitrofurantoin 
(12.1%) 
Azithromycin 
(7.5%) 
Azithromycin 
(3.2%) 
Clarithromycin 
(7.1%) 
Clarithromyci
n (8.0%) 
Amoxicillin and 
enzyme 
inhibitor 
(10.2%) 
Clarithromycin 
(7.0%) 
 Pheneticillin 
(4.2%) 
Pheneticillin 
(6.1%) 
Pheneticillin 
(9.0%) 
Pheneticillin         
(5.7%) 
  Nitrofurantoin 
(4.1%) 
Azithromycin 
(8.5%) 
Nitrofurantoin      
(4.4%) 
  Flucloxacillin 
(3.9%) 
Minocycline 
(6.6%) 
Doxycycline 
(3.1%) 
   Clarithromycin 
(6.3%) 
Flucloxacillin  
(3.0%) 
   Flucloxacillin 
(5.2%) 
Sulfamethoxazole
/trimethoprim       
 (2.8%) 
   Trimethoprim 
(3.5%) 
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Table 1b. Antibiotics that cover 90% of all antibiotic prescriptions (DU90%) by age categories in 
the United Kingdom (1995-2010) 
Age 0-<1 years Age 1-<5 years 
Age 5-<12 
years 
Age 12-<18 
years 
Overall 
Amoxicillin 
(64.6%) 
Amoxicillin 
(54.9%) 
Amoxicillin 
(41.9%) 
Amoxicillin 
(22.3%) 
Amoxicillin 
(44.0%) 
Erythromycin   
(9.5%) 
Erythromycin   
(10.1%) 
Phenoxymethyl 
-penicillin *  
(16.6%) 
Phenoxymethyl
-penicillin *  
(17.4%) 
Phenoxymethyl-
penicillin*         
(12.9%) 
Flucloxacillin 
(6.3%) 
Phenoxymethyl
-penicillin* 
(8.8%) 
Flucloxacillin 
(11.3%) 
Flucloxacillin   
(11.8%) 
Erythromycin 
(10.3%) 
Trimethoprim   
(5.2%) 
Flucloxacillin   
(6.7%) 
Erythromycin   
(9.8%) 
Erythromycin   
(11.5%) 
Flucloxacillin 
(9.3%) 
Phenoxymethyl
-penicillin* 
(4.2%) 
Trimethoprim   
(5.6%) 
Trimethoprim   
(5.8%) 
Oxytetracycline 
(7.8%) 
Trimethoprim    
(5.5%) 
Cefalexin         
(2.8%) 
Amoxicillin 
and enzyme 
inhibitor           
(4.3%) 
Amoxicillin 
and enzyme 
inhibitor           
(4.6%) 
Trimethoprim  
(5.0%) 
Amoxicillin and 
enzyme 
inhibitor             
(4.0%) 
  Cefalexin         
(3.8%) 
Lymecycline    
(4.8%) 
Cefalexin           
(3.4%) 
   Minocycline     
 (4.3%) 
Oxytetracycline 
 (1.8%) 
   Amoxicillin 
and enzyme 
inhibitor           
(3.0%) 
 
   Cefalexin         
(2.8%) 
 
* Phenoxymethylpenicillin is commonly known as penicillin V. 
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Table 1c. Antibiotics that cover 90% of all antibiotic prescriptions (DU90%) by age categories in 
Italy (2001-2010) 
Age 0-<1 years Age 1-<5 years Age 5-<12 years Age 12-<14 years Overall 
Amoxicillin 
(33.5%) 
Amoxicillin 
(25.7%) 
Amoxicillin and 
enzyme 
inhibitor 
(24.5%) 
Amoxicillin and 
enzyme inhibitor  
(25.6%) 
Amoxicillin 
(25.2%) 
Amoxicillin and 
enzyme 
inhibitor 
(21.4%) 
Amoxicillin and 
enzyme 
inhibitor 
(22.8%) 
Amoxicillin 
(22.9%) 
Amoxicillin 
(21.2%) 
Amoxicillin 
and enzyme 
inhibitor 
(23.4%) 
Clarithromycin 
(8.6%) 
Cefaclor 
(10.6%) 
Azithromycin 
(11.6%) 
Azithromycin 
(15.2%) 
Azithromycin 
(10.2%) 
Cefaclor    
(8.4%) 
Azithromycin 
(9.5%) 
Clarithromycin 
(10.2%) 
Clarithromycin 
(12.8%) 
Clarithromycin 
(9.2%) 
Azithromycin  
(6.0%) 
Clarithromycin  
(8.3%) 
Cefixime   
(7.6%) 
Cefixime       
(6.7%) 
Cefaclor 
(8.8%) 
Cefixime   
(5.0%) 
Cefixime   
(7.0%) 
Cefaclor   
(7.2%) 
Cefpodoxime 
(3.5%) 
Cefixime 
(7.1%) 
Ceftibuten 
(3.9%) 
Ceftibuten 
(3.8%) 
Cefpodoxime 
(4.1%) 
Cefuroxime  
(2.3%) 
Cefpodoxime 
(3.6%) 
Clofoctol  
(3.5%) 
Cefpodoxime 
(3.5%) 
Ceftibuten 
(2.9%) 
Cefaclor       
(2.0%) 
Ceftibuten 
(3.4%) 
   Ceftibuten     
(1.4%) 
 
 
  
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
26 
 
Table 2. Ratio of broad to narrow-spectrum penicillins, cephalosporins and macrolides users per 
database, age category and calendar year 
 
The ratio between the number of users of broad-spectrum penicillins, cephalosporins and 
macrolides (J01CR, J01DC, J01DD and J01F [without J01FA01]) and the number of users of 
narrow-spectrum antibiotics (J01CE, J01DB and J01FA01). 
Abbreviations: NL=the Netherlands; UK=the United Kingdom; It=Italy; yrs=years 
  
Broad/Narrow-spectrum antibiotics (B/N) ratio 
 2001 2006 2010 Overall 
 NL UK IT NL UK IT NL UK IT NL UK IT 
0-<1 yrs 5.9 0.3 27.1 6.5 0.3 66.8 6.6 0.4 149.5 5,7 0.3 60.8 
1-<5 yrs 2.8 0.3 38.2 4.1 0.3 72.5 5.0 0.4 360.7 3,9 0.4 100.1 
5-<12 yrs 2.8 0.2 12.9 2.9 0.2 55.9 4.0 0.3 173.3 3,4 0.2 61.0 
12-<14 yrs 2.5 0.2 9.4 2.2 0.2 40.8 3.3 0.3 114.5 2,6 0.2 60.3 
14-<18 yrs 1.5 0.1 - 2.1 0.2 - 2.4 0.3 - 2.0 0.2 - 
All ages 2.6 0.2 19.2 3.1 0.3 62.7 3.2 0.3 217.9 3,2 0.3 74.7 
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Table 3. Ratio of users of amoxicillin to users of broad-spectrum penicillins, cephalosporins and 
macrolides per database, age category and calendar year 
Amoxicillin/Broad-spectrum antibiotics (A/B) ratio 
 2001 2006 2010 Overall 
 NL UK IT NL UK IT NL UK IT NL UK IT 
0-<1 yrs 2,0 11,2 1,3 4,0 11,0 0,7 4,7 10,1 0,6 3,6 10,2 0,8 
1-<5 yrs 1,6 7,0 0,9 1,9 6,9 0,5 2,3 6,7 0,4 2,0 6,4 0,5 
5-<12 yrs 1,0 6,0 0,7 1,4 5,7 0,4 1,5 5,1 0,3 1,4 5,6 0,4 
12-<14 yrs 0,8 5,7 0,7 1,2 4,8 0,4 1,1 4,0 0,3 1,1 5,0 0,4 
14-<18 yrs 0,6 4,6 - 0,5 3,7 - 0,5 2,9 - 0,6 3,8 - 
All ages 1,2 6,6 0,8 1,6 6,1 0,5 1,7 5,4 0,3 1,6 6,0 0,5 
 
The ratio between the number of users of amoxicillin (J01CA04) and the number of users of 
broad- spectrum penicillins, cephalosporins and macrolides (J01CR, J01DC, J01DD and J01F 
(without J01FA01])  
Abbreviations: NL=the Netherlands; UK=the United Kingdom; It=Italy; yrs=years 
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Figure 1. 
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Figure 2. 
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Figure 3. 
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